Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat

European Journal of Neuroscience

Volumn 21, Issue 7, 2005, Pages 1911-1920

  Iczkiewicz, Joanna ^a   Rose, Sarah ^a   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Glial cells; Inflammation; Osteopontin; Parkinson's disease; Substantia nigra

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOSYLATED PROTEIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; OSTEOPONTIN; PHOSPHOPROTEIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN REGION; CELL ACTIVATION; CELL DEATH; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GLIA CELL; GLIOSIS; IMMUNOREACTIVITY; INFLAMMATION; MACROPHAGE; MALE; MICROGLIA; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SUBSTANTIA NIGRA; TIME SERIES ANALYSIS;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD11B; CELL COUNT; DOPAMINE; ECTODYSPLASINS; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIPOPOLYSACCHARIDES; MALE; MEMBRANE PROTEINS; NEUROGLIA; NEURONS; OSTEOPONTIN; RATS; RATS, WISTAR; SIALOGLYCOPROTEINS; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 18844407075     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2005.04009.x     Document Type: Article

References (60)

1. Aloisi, F. (2001) Immune function of microglia. Glia, 36, 165-179.
2. Arimoto, T. & Bing, G. (2003) Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol. Dis., 12, 35-45.
3. Banati, R.B., Gehrmann, J., Schubert, P. & Kreutzberg, G.W. (1993) Cytotoxicity of microglia. Glia, 7, 111-118.
4. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. & Seitelberger, F. (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci., 20, 415-455.
5. Boka, G., Anglade, P., Wallach, D., Javoy-Agid, F., Agid, Y. & Hirsch, E.C. (1994) Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett., 19 (172), 151-154.
6. Bronstein, D.M., Perez-Otano, I., Sun. V, Mullis Sawin, S.B., Chan, J., Wu, G.C., Hudson, P.M., Kong, L.Y., Hong, J.S. & McMillian, M.K. (1995) Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res., 704, 112-116.
7. Castano, A., Herrera, A.J., Cano, J. & Machado, A. (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem., 70, 1584-1592.
8. Castano, A., Herrera, A.J., Cano, J. & Machado, A. (2002) The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J. Neurochem., 81, 150-157.
9. Chabas, D., Baranzini, S.E., Mitchell, D., Bernard, C.C., Rittling, S.R., Denhardt, D.T., Sobel, R.A., Lock, C., Karpuj, M., Pedotti, R., Heller, R., Oksenberg, J.R. & Steinman, L. (2001) The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science, 294, 1731-1735.
10. Choi, J.S., Park, H.J., Cha, J.H., Chung, J.W, Chun, M.H. & Lee, M.Y. (2003) Induction and temporal changes of osteopontin mRNA and protein in the brain following systemic lipopolysaccharide injection. J. Neuroimmunol., 141, 65-73.
11. Damier, P., Hirsch, E.C., Zhang, P., Agid, Y. & Javoy-Agid, F. (1993) Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience, 52, 1-6.
12. Denhardt, D.T. & Guo, X. (1993) Osteopontin: a protein with diverse functions. FASEB J., 7, 1475-1482.
13. Denhardt, D.T., Giachelli, C.M. & Rittling, S.R. (2001a) Role of osteopontin in cellular signaling and toxicant injury. Annu. Rev. Pharmacol. Toxicol., 41, 723-749.
14. Denhardt, D.T., Noda, M., O'Regan, A.W., Pavlin, D. & Berman, J.S. (2001b) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest, 107, 1055-1061.
15. Desagher, S., Glowinski, J. & Premont, J. (1996) Astrocytes protect neurons from hydrogen peroxide toxicity. J. Neurosci., 16, 2553-2562.
16. Ellison, J.A., Barone, F.C. & Feuerstein, G.Z. (1999) Matrix remodeling after stroke. De novo expression of matrix proteins and integrin receptors. Ann. N.Y. Acad. Sci., 890, 204-222.
17. Farkas, E., De Jong, G.I., de Vos, R.A., Jansen Steur, E.N. & Luiten, P.G. (2000) Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol. (Berl.), 100, 395-402.
18. Gao, H.M., Jiang, J., Wilson, B., Zhang, W., Hong, J.S. & Liu, B. (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem., 81, 1285-1297.
19. Giachelli, C.M. & Steitz, S. (2000) Osteopontin: a versatile regulator of inflammation and biomineralization [In Process Citation]. Matrix Biol., 19, 615-622.
20. Guo, H., Cai, C.Q., Schroeder, R.A. & Kuo, P.C. (2001) Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. J. Immunol, 166, 1079-1086.
21. Hasegawa, Y, Inagaki, T., Sawada, M. & Suzumura, A. (2000) Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease. Acta Neurol. Scand., 101, 159-164.
22. Herrera, A.J., Castano, A., Venero, J.L., Cano, J. & Machado, A. (2000) The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis., 7, 429-447.
23. Hirsch, E.C., Breidert, T., Rousselet, E., Hunot, S., Hartmann, A. & Michel, P.P. (2003) The role of glial reaction and inflammation in Parkinson's disease. Ann. N.Y. Acad. Sci., 991, 214-228.
24. Hisanaga, K., Asagi, M., Itoyama, Y. & Iwasaki, Y. (2001) Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease. Arch. Neurol, 58, 1580-1583.
25. Hunot, S. & Hirsch, E.C. (2003) Neuroinflammatory processes in Parkinson's disease. Ann. Neurol, 53 (Suppl. 3), S49-S58.
26. Hwang, S.M., Wilson, P.D., Laskin, J.D. & Denhardt, D.T. (1994) Age and development-related changes in osteopontin and nitric oxide synthase mRNA levels in human kidney proximal tubule epithelial cells: contrasting responses to hypoxia and reoxygenation. J. Cell Physiol., 160, 61-68.
27. Iczkiewicz, J., Rose, S. & Jenner, P. (2004) Osteopontin (Eta-1) is present in the rat basal ganglia. Brain Res. Mol. Brain Res., 132, 64-72.
28. Iravani, M.M., Kashefi, K., Mander, P., Rose, S. & Jenner, P. (2002) Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience, 110, 49-58.
29. Kim, J.H., Skates, S.J., Uede, T., Wong, K.K., Schorge, J.O., Feltmate, C.M., Berkowitz, R.S., Cramer, D.W. & Mok, S.C. (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA, 287, 1671-1679.
30. Kirk, J., Plumb, J., Mirakhur, M. & McQuaid, S. (2003) Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J. Pathol., 201, 319-327.
31. Knott, C., Stern, G. & Wilkin, G.P. (2000) Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell Neurosci., 16, 724-739.
32. Koguchi, Y. Kawakami, K., Uezu, K., Fukushima, K., Kon, S., Maeda, M., Nakamoto, A., Owan, I., Kuba, M., Kudeken, N., Kadota, J.I., Mukae, H., Kohno, S., Uede, T. & Saito, A. (2003) High plasma osteopontin level and its relationship with IL-12-mediated Th1 response in tuberculosis. Am. J. Respir. Crit. Care Med., 167, 1355-1359.
33. Koutsilieri, E., Scheller, C., Grunblatt, E., Nara, K., Li, J. & Riederer, P. (2002) Free radicals in Parkinson's disease. J. Neurol., 249 (Suppl. 2). II1-II5.
34. Kreutzbera, G.W. (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci., 19, 312-318.
35. Kullberg, S., Aldskogius, H. & Ulfhake, B. (2001) Microglial activation, emergence of ED1-expressing cells and clusterin upregulation in the aging rat CNS, with special reference to the spinal cord. Brain Res., 899, 169-186.
36. Langston, J.W., Forno, L.S., Tetrud, J., Reeves, A.G., Kaplan, J.A. & Karluk, D. (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol, 46, 598-605.
37. Mayhan, W.G. (1998) Effect of lipopolysaccharide on the permeability and reactivity of the cerebral microcirculation: role of inducible nitric oxide synthase. Brain Res., 792, 353-357.
38. McGeer, E.G. & McGeer, P.L. (1997) The role of the immune system in neurodegenerative disorders. Mov. Disord., 12, 855-858.
39. McGeer, P.L. & McGeer, E.G. (2004) Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord., 10 (Suppl. 1), S3-S7.
40. McGeer, P.L., Itagaki, S., Boyes, B.E. & McGeer, E.G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 38, 1285-1291.
41. McGeer, P.L., Schwab, C., Parent, A. & Doudet, D. (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine administration. Ann. Neurol., 54, 599-604.
42. McNaught, K.S. & Jenner, P. (1999) Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4- phenylpyridinium-and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. J. Neurochem., 73, 2469-2476.
43. McNaught, K.S. & Jenner, P. (2000) Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation. Biochem. Pharmacol., 60, 979-988.
44. Minagar, A. & Alexander, J.S. (2003) Blood-brain barrier disruption in multiple sclerosis. Mult. Scler., 9, 540-549.
45. Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M. & Nagatsu, T. (1994a) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett., 180, 147-150.
46. Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K. & Nagatsu, T. (1994b) Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett., 165, 208-210.
47. Mogi, M., Harada, M., Narabayashi, H., Inagaki, H., Minami, M. & Nagatsu, T. (1996) Interleukin (IL)-1 beta, IL-2, 1L-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett., 211, 13-16.
48. Nau, G.J., Guilfoile, P., Chupp, G.L., Herman, J.S., Kim, S.J., Kornfeld, H. & Young, R.A. (1997) A chemoattractant cytokine associated with granulomas in tuberculosis and silicosis. Proc. Natl Acad. Sci. U.S.A, 94, 6414-6419.
49. O'Brien, E.R., Garvin, M.R., Stewart, D.K., Hinohara, T., Simpson, J.B., Schwartz, S.M. & Giachelli, C.M. (1994) Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler. Thromb., 14, 1648-1656.
50. O'Brien, K.D., Kuusisto, J., Reichenbach, D.D., Ferguson, M., Giachelli, C., Alpers, C.E. & Otto, C.M. (1995) Osteopontin is expressed in human aortic valvular lesions. Circulation, 92, 2163-2168.
51. Paxinos, G. & Watson, C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press Limited, London.
52. Rollo, E.E. & Denhardt, D.T. (1996) Differential effects of osteopontin on the cytotoxic activity of macrophages from young and old mice. Immunology, 88, 642-647.
53. Sakata, M., Tsuruha, J.I., Masuko-Hongo, K., Nakamura, H., Matsui, T., Sudo, A., Nishioka, K. & Kato, T. (2001) Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis. J. Rheumatol., 28, 1492-1495.
54. Scott, J.A., Weir, M.L., Wilson, S.M., Xuan, J.W., Chambers, A.F. & McCormack, D.G. (1998) Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. Am. J. Physiol., 275, H2258-H2265.
55. Singh, K., Balligand, J.L., Fischer, T.A., Smith, T.W. & Kelly, R.A. (1995) Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. Role in regulation of inducible nitric oxide synthase. J. Biol. Chem., 270, 28 471-28 478.
56. Tomas-Camardiel, M., Rite, I., Herrera, A.J., de Pablos, R.M., Cano, J., Machado, A. & Venero, J.L. (2004) Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol. Dis., 16, 190-201.
57. Vila, M., Jackson-Lewis, V., Guegan, C., Wu, D.C., Teismann, P., Choi, D.K., Tieu, K. & Przedborski, S. (2001) The role of glial cells in Parkinson's disease. Curr. Opin. Neurol., 14, 483-489.
58. Weber, G.F. (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim. Biophys. Acta, 1552, 61-85.
59. Weber, G.F., Adler, G. & Asnkar, S. (1999) Osteopontin in oxidative stress responses. In Ruffolo, R.R. Jr, Feuerstein, G.Z., Hunter, A.J., Poste, G. & Metcalf, B.W. (Eds), Inflammatory Cells and Mediators in CNS Diseases. Harwood Academic Publishers, Amsterdam, pp. 97-112.
60. Zeng, B.Y., Jolkkonen, J., Jenner, P. & Marsden, C.D. (1995) Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Neuroscience, 66, 19-28.